Tirzepatide is a research compound intended solely for in vitro and preclinical research use. It is not intended for human self-administration, veterinary use, or any application outside of a licensed research context. This article is provided for scientific and educational purposes only.
22.5% mean body weight reduction at 72 weeks. That number — from the SURMOUNT-1 Phase 3 trial — didn't just set a new benchmark for pharmacological metabolic research. It signalled that the ceiling set by GLP-1 monoagonism was not a ceiling at all.
Tirzepatide (LY3298176, Eli Lilly) is the first approved dual GIP/GLP-1 receptor agonist, and the compound that forced a fundamental reassessment of GIP's role in metabolic regulation. For years, glucose-dependent insulinotropic polypeptide was considered a therapeutically marginal incretin — potentially pro-lipogenic, certainly redundant alongside GLP-1. The SURPASS clinical programme dismantled that assumption systematically.
This research guide covers the molecular basis of tirzepatide's mechanism, key datasets from the SURPASS and SURMOUNT programmes, pharmacokinetics for research applications, and contextual comparison with semaglutide and retatrutide.
🔬 Related Research Compound
Retatrutide (LY3437943) — triple GLP-1/GIP/glucagon receptor agonist — is the subject of active Phase 3 research (TRIUMPH programme). A closely related compound adding the glucagon receptor axis absent from tirzepatide, available research-grade at UNIK LAB.
Contents
- What Is Tirzepatide? (LY3298176)
- The Dual Agonist Mechanism: GIP + GLP-1
- Timeline: From Incretins to Dual Agonism
- SURPASS Programme: Phase 3 Clinical Data
- SURPASS-2: Head-to-Head vs Semaglutide
- SURMOUNT-1: Obesity Phase 3 Data
- Tirzepatide vs Semaglutide vs Retatrutide: Full Comparison
- Pharmacokinetics: Half-Life and Research Dosing
- Reconstitution Protocol for Research Studies
- Safety Profile in Published Trials
- Current Regulatory Status
- FAQ
What Is Tirzepatide? (LY3298176)
Tirzepatide is a synthetic 39-amino acid peptide developed by Eli Lilly as a dual agonist at two hormone receptors central to metabolic regulation: the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R). The internal Eli Lilly compound designation is LY3298176.
Core identifiers:
- CAS Number: 2023788-19-2
- Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈
- Molecular Weight: ~4,813 g/mol
- Structure: 39 modified amino acids, GIP-GLP-1 chimeric sequence, C20 fatty diacid chain
- Half-life: ~5 days (enabling once-weekly subcutaneous dosing in clinical research)
The sequence is engineered as a chimera — drawing structural elements from both GIP and GLP-1 peptides to achieve meaningful agonism at both receptors simultaneously. The C20 fatty diacid chain conjugated to a lysine residue enables serum albumin binding — the same lipidation strategy that extended the half-life of semaglutide, applied with a longer chain variant.
Tirzepatide (as Mounjaro®) was approved by the FDA in May 2022 for type 2 diabetes management, and (as Zepbound®) in November 2023 for chronic weight management. These approvals cover licensed clinical use under physician supervision and do not extend to preclinical or in vitro research applications.
The Dual Agonist Mechanism: GIP + GLP-1
GLP-1R Agonism: The Established Incretin Pathway
GLP-1 (glucagon-like peptide-1) is released from intestinal L-cells in response to nutrient ingestion. At the β-cell level, GLP-1R activation stimulates glucose-dependent insulin secretion via the cAMP/PKA pathway — meaning insulin release occurs only in the presence of elevated glucose, providing a built-in safety mechanism against hypoglycaemia. Central GLP-1R signalling in the hypothalamus and nucleus tractus solitarius suppresses appetite and delays gastric emptying.
GIPR Agonism: The Reassessment
For decades, GIP was considered a problematic therapeutic target. In patients with type 2 diabetes, the insulinotropic effect of GIP is diminished, and some animal data suggested GIPR activation could promote lipogenesis.
Tirzepatide's data forced a complete revision. Samms RJ, Coskun T et al. demonstrated in the Journal of Clinical Investigation (2021, PMID 34003802) that GIPR agonism mediates weight-independent improvements in insulin sensitivity in obese mice. In adipose tissue, GIPR activation enhances insulin signalling and reduces ectopic lipid deposition through pathways distinct from GLP-1R. The combination creates a synergistic metabolic effect that neither receptor achieves independently.
Downstream Signalling
At both GIPR and GLP-1R, tirzepatide activates the canonical cAMP/PKA pathway through Gs protein coupling: receptor binding → Gαs activation → adenylyl cyclase → cAMP accumulation → PKA activation → downstream phosphorylation. At the β-cell: KATP channel closure, membrane depolarisation, Ca²⁺ influx, insulin exocytosis. In adipocytes and muscle: GLUT4 trafficking, lipid metabolism modulation. In the CNS: appetite suppression via hypothalamic and brainstem circuits.
Timeline: From Incretins to Dual Agonism (2005–2026)
2005: Exenatide becomes the first GLP-1R agonist approved. Modest efficacy (~3% weight loss). Proof-of-concept for the incretin approach.
2010: Liraglutide approved — once-daily, lipidation strategy, improved efficacy.
2017: Semaglutide Phase 3 (SUSTAIN programme) data: −14.9% weight loss. Assumed ceiling for GLP-1R monoagonism.
2018–2020: Tirzepatide Phase 1/2 data arrives. GIP/GLP-1 synergy hypothesis gains experimental support.
2021: SURPASS Phase 3 published. SURPASS-2 ( PMID 34170647): −5.5 pp more weight loss vs semaglutide 1 mg. The GLP-1 monoagonism ceiling is broken.
2022: FDA approves tirzepatide for T2D. SURMOUNT-1 data: −22.5% weight at 72 weeks.
2023: Tirzepatide approved for obesity (Zepbound). SURMOUNT-2 confirms efficacy in T2D + obesity population.
2024–2026: SURPASS-CVOT ongoing. Retatrutide advances to Phase 3 with the glucagon receptor as a third axis.
SURPASS Programme: Phase 3 Clinical Data Overview
SURPASS-3 (Ludvik B et al., Lancet 2021, PMID 34370970): Tirzepatide vs insulin degludec in T2D. At 52 weeks, tirzepatide 15 mg reduced HbA1c by −2.37% vs −1.34% for degludec. Weight: −12.9 kg vs +2.3 kg — a ~15 kg net differential in a T2D population.
SURPASS-4 (Del Prato S et al., Lancet 2021, PMID 34672967): Tirzepatide vs insulin glargine in T2D with elevated cardiovascular risk over 104 weeks. HbA1c: −2.58% vs −1.44%. Weight: −13.9 kg vs +1.9 kg. Tirzepatide reduced hypoglycaemia (≤54 mg/dL) by ~60% relative to insulin glargine.
SURPASS-2: Head-to-Head vs Semaglutide
Frías JP et al. New England Journal of Medicine, 2021, PMID 34170647.
Design: Randomised, double-blind, 40-week Phase 3. Tirzepatide (5, 10, 15 mg) vs semaglutide 1 mg weekly in 1,879 adults with T2D inadequately controlled on metformin. Primary endpoint: HbA1c change.
| Outcome | Tirz 5 mg | Tirz 10 mg | Tirz 15 mg | Sema 1 mg |
|---|---|---|---|---|
| HbA1c change | −2.01% | −2.24% | −2.30% | −1.86% |
| Body weight change | −7.6 kg | −9.3 kg | −11.2 kg | −5.7 kg |
| % reaching HbA1c <7.0% | 82% | 87% | 92% | 79% |
| % reaching HbA1c <5.7% | 28% | 36% | 45% | 19% |
The weight differential at 15 mg is the figure researchers cite most: −11.2 kg vs −5.7 kg, a difference of −5.5 kg over 40 weeks. Glucose-normalisation rates (HbA1c <5.7%) at 15 mg — 45% vs 19% for semaglutide — suggest tirzepatide's dual mechanism achieves a degree of metabolic normalisation that GLP-1 monoagonism does not reach in T2D populations.
SURMOUNT-1: Obesity Phase 3 Data
Jastreboff AM, Aronne LJ et al. New England Journal of Medicine, 2022, PMID 35658024.
Design: Phase 3, randomised, double-blind, placebo-controlled. 2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27 + comorbidities), without type 2 diabetes. Tirzepatide 5, 10, or 15 mg vs placebo, 72 weeks.
| Dose | Mean % weight change | % Achieving ≥5% loss | % Achieving ≥20% loss |
|---|---|---|---|
| Placebo | −2.4% | 35% | 3% |
| 5 mg | −15.0% | 85% | 30% |
| 10 mg | −19.5% | 89% | 50% |
| 15 mg | −22.5%* | 91% | 57% |
*On-treatment analysis. Primary analysis showed −20.9% at 72 weeks.
The 57% of participants achieving ≥20% weight loss at 15 mg is a benchmark figure. No approved pharmacological intervention had reached that proportion in a Phase 3 trial prior to this publication. The weight loss curve at 72 weeks had not fully plateaued at the highest doses.
Tirzepatide vs Semaglutide vs Retatrutide vs Liraglutide
↔ Scroll horizontally on mobile.
| Parameter | Tirzepatide (LY3298176) | Semaglutide | Retatrutide (LY3437943) | Liraglutide |
|---|---|---|---|---|
| CAS Number | 2023788-19-2 | 910463-68-6 | 2381089-83-2 | 204656-20-2 |
| Molecular Weight | ~4,813 g/mol | ~4,114 g/mol | ~4,732 g/mol | ~3,751 g/mol |
| Receptors Targeted | GLP-1R + GIPR | GLP-1R only | GLP-1R + GIPR + GCGR | GLP-1R only |
| Half-Life | ~5 days | ~7 days (sc) | ~6 days | ~13 hours |
| Max % Weight Loss | −22.5% (72 wk, SURMOUNT-1) | −14.9% (68 wk, STEP-1) | −24.2% (48 wk, Phase 2) | −8.0% (56 wk, Phase 3) |
| Clinical Stage (2026) | Approved FDA + EMA (T2D + obesity) | Approved FDA + EMA (T2D, obesity, CV) | Phase 3 (TRIUMPH) | Approved FDA + EMA |
| Research Advantage | Most Phase 3 dual agonist data; GIPR synergy mechanism; head-to-head vs semaglutide | Broadest evidence base; CV outcomes data; oral formulation | Strongest weight loss signal; unique GCGR axis; hepatic fat studies | Daily dosing for kinetic studies; longest track record |
| Research Limitation | No GCGR component; CVOT pending | No GIPR or GCGR component; lower efficacy ceiling | Phase 2 only; no CVOT data | Daily injection; lowest efficacy in class |
Weight loss figures from highest-dose arms in pivotal trials. Retatrutide figures are Phase 2. Data compiled from published sources for research comparison purposes.
Pharmacokinetics: Half-Life and Research Dosing

Tirzepatide's ~5-day half-life is the direct result of its lipidation architecture. The C20 fatty diacid chain at Lys²⁶ creates reversible, non-covalent binding to serum albumin, protecting the compound from renal filtration and proteolytic degradation.
Key pharmacokinetic parameters (from SURPASS clinical pharmacology data):
- Tmax: ~8–24 hours after subcutaneous administration
- Bioavailability (sc): ~80%
- Volume of distribution: ~10.3 L (primarily intravascular + lymphatic)
- Steady state: reached after approximately 4 weekly doses
- Peak-to-trough ratio: ~1.3–1.5 — relatively flat pharmacokinetic profile
For in vitro research applications:
Tirzepatide is used at nanomolar concentrations for receptor binding kinetics characterisation. Standard assay formats include cAMP accumulation (HTRF-based) in GLP-1R-expressing and GIPR-expressing HEK293 cells, and downstream insulin signalling via Western blot (phospho-Akt Ser473, phospho-IRS-1) in adipocyte or hepatocyte cell lines.
Reconstitution Protocol for Research Studies
Tirzepatide from UNIK LAB is supplied as lyophilised powder, typically 5 mg vials.
- Solvent: Sterile water for injection or bacteriostatic water. For cell culture, use sterile PBS to avoid benzyl alcohol cytotoxicity.
- Volume: For 1 mg/mL: add 5 mL to 5 mg vial. For 0.5 mg/mL: add 10 mL.
- Technique: Add solvent slowly along vial wall. Do not inject onto cake. Do not vortex. Gentle swirling 30–60 seconds.
- Storage post-reconstitution:
- Bacteriostatic water: 2–8°C, up to 28 days
- Sterile water: −20°C, use within 7 days; avoid freeze-thaw cycling
- Aliquot into single-use volumes before freezing
- Stability: Discard vials showing cloudiness, colour change, or visible precipitation.
For Certificate of Analysis (COA) verification, see the UNIK LAB COA verification guide. For reconstitution protocols applicable to acylated peptides, see the UNIK LAB reconstitution guide.
Safety Profile in Published Trials
Most common adverse events (dose-dependent, mild-to-moderate):
- Nausea: 12–23% (vs 5% placebo)
- Diarrhoea: 13–17%
- Vomiting: 6–10%
- Decreased appetite: 9–12%
- Constipation: 8–12%
Notable safety findings:
- Hypoglycaemia: In SURPASS-4, tirzepatide demonstrated ~60% relative reduction in hypoglycaemia vs insulin glargine. The glucose-dependent mechanism of both receptors provides intrinsic safety absent from exogenous insulin.
- Heart rate: Modest increase of ~2–4 bpm across SURPASS arms — GLP-1R class effect.
- Pancreatitis: Rates low and not statistically different from comparators.
Current Regulatory Status
As of April 2026:
- FDA: Approved as Mounjaro® (T2D, May 2022) and Zepbound® (obesity, November 2023)
- EMA: Approved as Mounjaro® for T2D and obesity
- Health Canada: Approved for T2D management
- Research use: Institutional compliance required for in vitro and preclinical research purchase and use
- SURPASS-CVOT: Cardiovascular outcomes trial ongoing; primary results anticipated 2025–2026
Researchers studying GLP-1 class mechanisms frequently pair tirzepatide (dual agonist reference) with semaglutide (monoagonist control) — the combination enables mechanistic isolation of GIPR-specific contributions to metabolic outcomes. See the Semaglutide Research Guide and the Retatrutide Research Guide for the full incretin class comparison.
Research FAQ
What is tirzepatide and how does it differ from semaglutide?
Tirzepatide (LY3298176) is a dual GIP/GLP-1 receptor agonist. Semaglutide targets only GLP-1R. The addition of GIPR agonism in tirzepatide produces synergistic effects on insulin sensitivity and weight regulation not achievable with GLP-1 monoagonism alone. In SURPASS-2 (PMID 34170647), tirzepatide 15 mg produced −5.5 kg greater weight loss than semaglutide 1 mg over 40 weeks. As a research compound, tirzepatide is not intended for human self-administration.
What were the main findings of the SURMOUNT-1 trial?
SURMOUNT-1 (Jastreboff AM et al., NEJM 2022, PMID 35658024): 2,539 adults, obesity/overweight without T2D, 72 weeks. Tirzepatide 15 mg: −22.5% mean weight vs −2.4% placebo. 57% achieved ≥20% weight loss at the highest dose — a benchmark not previously reached in a Phase 3 pharmacological trial.
How does GIPR agonism contribute to tirzepatide's mechanism?
Samms RJ et al. (J Clin Invest, 2021, PMID 34003802) demonstrated that GIPR agonism mediates weight-independent improvements in insulin sensitivity in obese mice. The mechanism operates through adipose tissue pathways distinct from GLP-1R signalling, amplifying the overall metabolic effect.
What is tirzepatide's half-life?
Approximately 5 days, achieved via C20 fatty diacid albumin-binding conjugation. Steady state with once-weekly dosing reached after ~4 doses. For in vitro research, cAMP accumulation assays at nanomolar concentrations are the standard format for receptor kinetics characterisation.
How does tirzepatide compare to retatrutide?
Tirzepatide targets GIP + GLP-1; retatrutide adds the glucagon receptor (GCGR). Retatrutide showed higher maximum weight loss in Phase 2 (−24.2% at 48 weeks). Tirzepatide has substantially more published Phase 3 data and regulatory approval. For hepatic fat and energy expenditure research, retatrutide's GCGR axis adds a signal tirzepatide cannot provide.
What is the regulatory status of tirzepatide as a research compound?
FDA and EMA approved for T2D and obesity in licensed clinical contexts. For preclinical and in vitro research, classified as a research compound requiring institutional compliance — clinical approvals do not govern research use.
What safety signals were observed in the SURPASS programme?
Primary AEs: nausea, diarrhoea, vomiting (GI, dose-dependent, mild-to-moderate). In SURPASS-4 (PMID 34672967), ~60% lower hypoglycaemia rates vs insulin glargine. Modest heart rate increase (~2–4 bpm) consistent with GLP-1R class effects.
Available from UNIK LAB
Research Peptides
Research-grade Research Peptides · HPLC verified ≥98% · COA included · 48h EU/UK dispatch
